The Supreme Court Just Ruled for Monsanto on Roundup — Here Is What It Means for Your Cancer Claim
You just read the headline. Monsanto won at the United States Supreme Court. Maybe you have a pending Roundup claim and your heart dropped. Maybe you used Roundup for years, you have non-Hodgkin lymphoma, and you were counting on the legal system to hold the company accountable — and now you are wondering whether the door just closed. We need you to hear this clearly before you read another word of news coverage: this ruling is a serious blow to one legal theory, but it is not the end of every Roundup case, and it is absolutely not a court ruling that Roundup is safe. The Supreme Court answered a question about who gets to decide what goes on a pesticide label — the federal government or a state jury. It did not conduct a scientific review of whether glyphosate causes cancer. Those are two different things, and the difference is where your remaining rights live.
We are going to walk you through exactly what happened, what it means for your specific situation, and what you should do in the days and weeks ahead. This is not a time to panic, and it is not a time to abandon a claim without understanding what still survives. It is a time to get honest, precise information from people who know how mass tort litigation actually works — not from a headline designed to make you click.
What the Supreme Court Actually Decided: The FIFRA Preemption Question
The case that reached the Supreme Court — and the ruling Monsanto won — centers on a federal law called the Federal Insecticide, Fungicide, and Rodenticide Act, known as FIFRA. FIFRA is the law that governs how pesticides are registered, labeled, and sold in the United States. Under FIFRA, the Environmental Protection Agency reviews and approves the label on every pesticide product before it reaches the market. Once the EPA approves a label, the manufacturer cannot change it without going back to the EPA.
Here is the provision at the center of everything — the express preemption clause in FIFRA:
“No State or political subdivision of a State may impose or continue in effect any requirements for labeling or packaging in addition to or different from those required under this subchapter.”
— 7 U.S.C. § 136v(b)
That sentence is the whole fight. Monsanto’s argument was simple and powerful: the EPA reviewed Roundup’s label and decided it did not need a cancer warning. If a state court jury then says Monsanto should have put a cancer warning on the label anyway, that jury is imposing a labeling requirement “in addition to or different from” what the EPA required — which FIFRA says states cannot do. The Supreme Court agreed with Monsanto.
In plain English: the Court ruled that because the federal government — through the EPA — approved Roundup’s label without requiring a cancer warning, state courts cannot hold Monsanto liable for failing to add one. The federal labeling regime under FIFRA preempts state-law failure-to-warn claims.
This is a preemption ruling. It is a legal ruling about the boundary between federal authority and state authority. It is not a scientific ruling about whether glyphosate causes cancer, and it is not a factual finding that Roundup is safe. Every news headline that says “Supreme Court rules Roundup doesn’t cause cancer” is wrong. The Court said nothing of the kind.
Why This Ruling Happened: The EPA-IARC Scientific War
To understand why this preemption question even reached the Supreme Court, you have to understand the deep disagreement at the heart of the Roundup litigation — two government bodies looking at the same chemical and reaching opposite conclusions.
The EPA has consistently taken the position that glyphosate is “not likely to be carcinogenic to humans.” That position has been stated in multiple EPA reviews and registration decisions over the years. It is the basis for the EPA’s decision not to require a cancer warning on Roundup’s label.
But in 2015, the International Agency for Research on Cancer — IARC, which is the cancer-research arm of the World Health Organization — classified glyphosate as “probably carcinogenic to humans” (Group 2A). IARC reached this conclusion after reviewing the available scientific evidence, including studies on agricultural workers exposed to glyphosate and laboratory studies of the chemical’s effects.
Those two positions cannot both be right, and the tension between them is the engine that has driven the entire Roundup mass tort. Plaintiffs argued that Monsanto knew about the cancer risk, manipulated the science, and should have warned users regardless of what the EPA’s label required. Monsanto argued that it complied with the EPA’s labeling regime and that state tort law cannot override that federal approval.
The Supreme Court’s ruling essentially says: when the federal regulator (EPA) decides no cancer warning is needed, state juries cannot second-guess that decision through failure-to-warn tort claims. The federal labeling regime controls.
What This Ruling Destroys: Failure-to-Warn Claims
The primary theory in Roundup litigation has been failure to warn. Tens of thousands of plaintiffs have alleged that Monsanto failed to adequately warn users that Roundup could cause cancer. That theory has been the backbone of the litigation — it was the theory behind the early trial verdicts that produced headline-grabbing awards against Monsanto.
If the Supreme Court held that FIFRA preempts state-law failure-to-warn claims — which is what Monsanto won — then that theory is likely foreclosed in every state and every federal court. The value of a pure failure-to-warn claim approaches zero. A court that would have let a jury decide whether Monsanto should have warned about cancer risk will now be required to dismiss that claim because the EPA’s labeling decision controls.
This is a significant defeat. We will not pretend otherwise. The failure-to-warn theory was the most accessible, most proven, and most widely pleaded path to recovery in the Roundup docket. Losing it changes the calculus for every pending plaintiff and every future filer.
But losing one theory is not losing the case — and that distinction is where your attention needs to go right now.
What Survives: Design Defect, Fraudulent Concealment, and Negligent Testing
Here is the critical question: does the FIFRA preemption ruling reach every theory of liability, or just failure-to-warn? The answer, based on the structure of FIFRA and the logic of preemption, is that the ruling should be limited to claims that would require a different or additional label warning. Three theories plausibly survive:
Design defect. A design-defect claim alleges that Roundup’s formulation is inherently dangerous — that the product itself was unreasonably dangerous when it was designed, regardless of what the label says. This theory does not necessarily require a different warning on the label. It challenges the product’s design, not its labeling. FIFRA’s preemption clause specifically targets “requirements for labeling or packaging” — not requirements about product design. A state tort law imposing liability for a dangerous design is not the same as imposing a labeling requirement, and there is a strong argument that design-defect claims fall outside the scope of FIFRA preemption. Design defect faces robust general-causation defenses — Monsanto will argue the science does not support that glyphosate causes NHL — but it is not foreclosed by the preemption ruling.
Fraudulent concealment. This is the theory with the most teeth after the ruling. Fraudulent concealment alleges that Monsanto intentionally suppressed or manipulated scientific evidence regarding glyphosate’s carcinogenicity — that the company knew about the cancer risk and actively hid it from the public, from regulators, and from the scientific community. This is an intentional-tort theory, not a labeling theory. It does not require a different warning on the label; it requires proof that Monsanto lied about what it knew. The internal Monsanto documents already in the MDL discovery record — emails, memos, ghostwriting allegations, regulatory-correspondence timelines — are the evidence that powers this claim. Fraudulent concealment may survive preemption because it targets the company’s conduct in deceiving the public and regulators, not the content of the EPA-approved label. And fraudulent concealment supports punitive damages if substantiated, which makes it the highest-value surviving theory.
Negligent failure to test. This theory alleges that Monsanto failed to conduct adequate long-term carcinogenicity studies before bringing Roundup to market. It targets the company’s pre-market conduct — what it did or did not do before the EPA ever saw a label — rather than the label content itself. A duty to test is not a labeling requirement, and there is an argument that this theory falls outside FIFRA preemption for the same structural reason as design defect.
The generalist filing a Roundup complaint pleads failure to warn and stops. The attorney who reads this ruling and understands its scope pleads the surviving theories with specificity and builds the evidence to support each one. That is the difference between a case that dies on a motion to dismiss and a case that survives to reach a jury.
Bayer and Monsanto: The Corporate Defendant You Are Actually Suing
Bayer AG, the German pharmaceutical and life-sciences conglomerate, acquired Monsanto Company in 2018 for approximately $63 billion. With that acquisition, Bayer assumed the litigation exposure for Roundup claims worldwide. Monsanto — the St. Louis-based agricultural biotechnology company that developed and marketed Roundup for decades — is now a wholly-owned subsidiary of Bayer. In the litigation, the caption defendant is still “Monsanto Company,” but the entity with the deep pockets, the global balance sheet, and the settlement authority is Bayer.
This matters because the Supreme Court ruling does not change who the defendant is or where the money sits. Bayer is one of the largest pharmaceutical and chemical companies in the world. It has the resources to fight every remaining case to verdict, and it has the resources to settle the cases it chooses to settle. The ruling shifts the settlement leverage toward Bayer — failure-to-warn claims that previously carried significant value are now weaker — but Bayer still faces tens of thousands of unresolved cases, surviving theories that carry real exposure, and the reputational cost of continued litigation over a product that the world’s leading cancer authority classified as “probably carcinogenic.”
The Roundup multidistrict litigation — MDL No. 2741 — has been centralized in the Northern District of California before Judge Vince Chhabria. As of the most recent JPML report, approximately 3,900 actions were pending in the MDL, with additional cases in state courts across the country, particularly in Missouri where Monsanto is headquartered. The ruling will ripple through every one of those dockets, but it does not automatically dismiss them. Each case must be evaluated individually against the ruling’s actual scope.
The Medicine: Non-Hodgkin Lymphoma and Your Proof of Harm
Non-Hodgkin lymphoma is a cancer that begins in the lymphatic system — the body’s network of lymph nodes, spleen, and other organs that are part of the immune system. It is a blood cancer, specifically a cancer of white blood cells called lymphocytes. There are many subtypes of NHL, and the subtype matters both for your medical treatment and for the strength of your legal claim.
The most common subtype is diffuse large B-cell lymphoma (DLBCL), an aggressive but often treatable form. Other subtypes include follicular lymphoma (typically slower-growing), mantle cell lymphoma, and marginal zone lymphoma. Your pathology report — the document that identifies the specific subtype — is a foundational piece of evidence in any Roundup case, regardless of which liability theory survives.
Diagnosis requires a lymph node biopsy, followed by pathology examination and immunophenotyping. Staging involves CT or PET imaging and bone marrow biopsy. Treatment depends on the subtype and stage but commonly involves chemotherapy regimens (such as R-CHOP for DLBCL), radiation, immunotherapy, and in some cases stem cell transplantation. The medical costs are substantial — induction chemotherapy alone can run into the hundreds of thousands of dollars, and a stem cell transplant can push costs well into seven figures.
The proof problem the defense exploits in every Roundup case is causation. Non-Hodgkin lymphoma has many known causes and risk factors — age, immune system suppression, certain infections, family history — and glyphosate is not the only possible explanation for any individual’s diagnosis. The defense will argue that your NHL came from something else, or from nothing identifiable, and that you cannot prove glyphosate caused your specific cancer.
The counter lives in your exposure history. The strength of a Roundup case — on any surviving theory — depends on documenting the intensity, duration, and frequency of your glyphosate exposure. How many years did you use Roundup? How often did you apply it? Did you mix concentrates? Did you spray without protective equipment? Did you get the product on your skin or breathe the mist? The more detailed and specific your exposure history, the stronger the causal connection between your Roundup use and your NHL diagnosis — and that connection is what every surviving theory requires.
The Evidence You Need to Preserve Right Now
The evidence in a Roundup case falls into four categories, and each has a different urgency level.
Your individual exposure history is the evidence most at risk of degrading. Human memory fades. The details of when you bought Roundup, how often you used it, and how you applied it become less precise with every passing month. If you have not already done so, write down everything you can remember about your Roundup use — the years, the frequency, the products (Roundup concentrate, ready-to-use, professional grade), the settings (your lawn, your farm, your workplace), and the protective equipment you did or did not wear. Purchase records, credit card statements, and old receipts can corroborate your recall. If you used Roundup in an occupational setting — as a farmer, landscaper, groundskeeper, nursery worker, or parks employee — employment records, pesticide application logs, and coworker testimony can establish your exposure with far more precision than memory alone. This evidence is moderately time-sensitive: it does not disappear on a fixed legal schedule, but it degrades as memory fades and records are discarded.
Your medical records are the foundation of your damages case. You need your complete oncology file — the pathology report that identified your NHL subtype, your treatment records, your imaging, your chemotherapy administration records, your hospitalization records, and your follow-up care plan. These records are retained per HIPAA and state retention requirements, so they are relatively safe from destruction, but you should authorize their release to your attorney promptly. If you have undergone a stem cell transplant or are in active treatment, the records are accumulating — make sure they are being collected as they are generated.
Monsanto and Bayer internal corporate documents are already in the MDL discovery record. Emails, internal memos, scientific study drafts, regulatory correspondence, and documents showing what Monsanto knew about glyphosate’s potential carcinogenicity — and when — have been produced through MDL discovery. These documents are the evidence that powers fraudulent concealment claims, and they are generally available to plaintiffs participating in the MDL. However, protective orders in the MDL may restrict access for non-participating plaintiffs. If you have a pending claim, your attorney should already have access to the MDL document repository. If you are considering filing, the availability of these documents is a factor in deciding whether and how to proceed.
The IARC monograph and EPA registration file are public regulatory records with stable availability. The IARC classification of glyphosate as “probably carcinogenic” is published and accessible. The EPA’s registration review file for glyphosate — including the agency’s carcinogenicity assessment and its communications with Monsanto — is also part of the public regulatory record. These documents establish the scientific-regulatory disagreement that sits at the heart of every Roundup case, and they support expert testimony on general causation regardless of which liability theory survives.
What a Roundup Case Is Worth After This Ruling
Let us be honest about the numbers, because false hope is worse than honest assessment.
For plaintiffs whose only viable theory was failure to warn — and whose cases cannot be re-pleaded on a surviving theory — the value of those claims approaches zero if the preemption ruling is fully applied. A fully preempted failure-to-warn claim is a claim that a court must dismiss. That is the hard truth of this ruling, and we will not dress it up.
For plaintiffs with viable alternative theories — particularly fraudulent concealment supported by internal Monsanto documents showing scienter — individual case values may remain in the seven-figure range. The specific value depends on exposure intensity, cancer subtype, jurisdiction, treatment costs, lost wages, and the availability of punitive damages in the relevant state. A plaintiff with decades of heavy occupational Roundup exposure, a confirmed NHL diagnosis, and internal documents showing Monsanto’s knowledge of potential carcinogenicity may still have a case worth two to five million dollars on a surviving theory — but that case now requires more work, different pleading, and a more sophisticated legal team than the same case required before this ruling.
The ruling’s greatest impact is on aggregate settlement leverage. Before the ruling, the threat of tens of thousands of failure-to-warn claims — each carrying the potential for a plaintiff verdict and punitive damages — drove Bayer’s settlement calculus. With failure-to-warn claims potentially eliminated, the aggregate pressure on Bayer decreases, and global settlement values shift downward. Bayer may still choose to settle remaining cases to avoid the cost and uncertainty of trial, but the price per case will likely be lower than it was before the ruling.
Past results depend on the facts of each case and do not guarantee future outcomes. No attorney can promise you a specific recovery, and any lawyer who tells you your case is worth a fixed dollar amount before reviewing your exposure history, your medical records, and the specific facts of your situation is not giving you honest advice.
The Insurance and Corporate Defense Playbook After This Ruling
We know how corporate defendants and their insurers operate after a major defense victory, because our own Lupe Peña spent years inside a national insurance-defense firm before joining this firm. He sat in the rooms where adjusters and their software decided how to deny, delay, and devalue people exactly like you. He knows the playbook from the inside, and now he uses that knowledge for injured clients. Here are the plays you should expect, and the counter to each one.
Play 1: “The Supreme Court said Roundup is safe.” Within days of the ruling, corporate defense lawyers and claims adjusters will begin framing this as a scientific vindication. They will tell plaintiffs, judges, and the public that the highest court in the land ruled Roundup does not cause cancer. This is a deliberate mischaracterization. The ruling is a preemption decision about labeling authority, not a scientific finding about carcinogenicity. The counter is precise: the Supreme Court said state juries cannot require a warning the EPA did not require — it said nothing about whether glyphosate actually causes cancer, and the IARC classification remains unchanged.
Play 2: “All your claims are now preempted — take this reduced settlement or get nothing.” Defense counsel will overstate the ruling’s scope, arguing that every Roundup claim — not just failure-to-warn — is now barred. They will use this to pressure plaintiffs into accepting quick, deeply discounted settlements before surviving theories are developed or pleadings are amended. The counter is legal: the preemption clause targets “requirements for labeling or packaging,” and design-defect, fraudulent-concealment, and negligent-testing claims do not necessarily impose labeling requirements. A knowledgeable attorney will refuse to accept the defense’s expansive reading of the ruling and will test the actual scope in court.
Play 3: “Your case is weak now — we will move to dismiss and you will lose.” The defense will file motions to dismiss arguing that the preemption ruling kills every Roundup case. For pure failure-to-warn claims, they may be right. For cases pleaded on surviving theories, the motion will fail if the complaint is properly constructed — but only if the attorney read the ruling, understood its limits, and amended the pleading to target theories that fall outside the preemption scope. The counter is preparation: the time to amend pleadings is now, before the defense’s motion lands, not after.
Play 4: “Settlement offers expire soon.” Claims departments will set artificial deadlines on reduced settlement offers, using the ruling as leverage to create false urgency. The counter is patience: a settlement offer should be evaluated against the actual value of your surviving claims, not against a defense-manufactured deadline. If your attorney cannot identify a surviving theory worth pursuing, a discounted settlement may be the right call. But that decision should be made after a case-by-case review, not under pressure from an adjuster who is counting on you not knowing the difference between a preemption ruling and a safety finding.
The First Steps to Take Right Now
If you have a pending Roundup claim, do not abandon it without a case-by-case review. Do not sign anything from Monsanto’s lawyers, their insurers, or any claims administrator without having it reviewed by your own attorney. Do not post on social media about your case, your diagnosis, or the ruling. Do not give a recorded statement to anyone from the defense side.
What you should do — today — is document your exposure history in writing if you have not already. Write down every detail you can recall about your Roundup use: when you started, when you stopped, how often you applied it, what products you used, where you bought them, what you were doing when you used them, and whether you wore gloves, a mask, or other protective equipment. Obtain copies of your complete medical records — pathology report, treatment history, current medications, follow-up schedule. If you have purchase records, old receipts, or employment records showing pesticide use, gather them.
And contact qualified counsel — not just any lawyer, but one who understands mass tort litigation, has read this ruling, and can tell you whether your specific case has a surviving theory. The consultation should be free, and the attorney should be able to explain in plain language which of your claims are affected and which may continue. If the attorney cannot answer that question, or tells you every Roundup case is now dead without reviewing your individual facts, that attorney has not done the work this ruling demands.
The Statute of Limitations: Your Deadline Has Not Changed
The Supreme Court’s ruling does not extend or toll the statute of limitations on your Roundup claim. Your deadline to file is still governed by the law of the state where you live or where your exposure occurred — and those deadlines vary. In most states, the personal-injury statute of limitations runs between two and six years. For wrongful-death claims, the deadline is often shorter — typically one to three years from the date of death.
For toxic exposure cases like Roundup, many states apply a discovery rule, which means the clock may not start running on the date you were exposed to glyphosate — it may start on the date you discovered, or reasonably should have discovered, that your cancer was connected to your Roundup use. This is critically important because many Roundup plaintiffs used the product for years or decades before developing NHL, and the connection between exposure and disease may not have been apparent until a diagnosis was made.
But the discovery rule is not unlimited. Some states impose an outer deadline — a statute of repose — that can cut off a claim even before discovery. And the specific formulation of the discovery rule varies from state to state. We cannot tell you your exact deadline without knowing your state, your diagnosis date, and when you first connected your illness to Roundup. What we can tell you is this: if you are sitting on a potential Roundup claim and waiting to see how the legal situation settles, the clock on your claim is running — and this ruling does not stop it. If you are in a state with a two-year personal-injury deadline and your diagnosis was two years ago, you may already be at the edge of the window.
The safest move is to talk to an attorney now, not after the legal dust settles. If you would like to explore your toxic tort claim options, we can help you understand the deadline that applies to your specific situation.
Why the Preemption Ruling May Reach Beyond Roundup
One of the most significant — and least discussed — aspects of this ruling is its potential reach beyond the Roundup litigation. FIFRA governs every pesticide and herbicide sold in the United States. If the Supreme Court held that FIFRA’s preemption clause bars state-law failure-to-warn claims for glyphosate, that same logic would apply to any pesticide or herbicide registered under FIFRA.
This means that plaintiffs injured by any EPA-registered pesticide — whether it is a farm chemical, a lawn-care product, or an industrial herbicide — may face the same preemption barrier on failure-to-warn claims. The ruling could reshape the entire landscape of pesticide product-liability litigation, not just the Roundup docket. If you have a claim involving a different FIFRA-registered product, this ruling may affect your case as well, and you should consult with an attorney who understands both the specific product and the preemption analysis.
Who We Are and How We Can Help
Ralph Manginello has spent 27-plus years licensed in courtrooms, including federal court, since his admission to the Texas Bar in 1998. He was a journalist before he was a lawyer — he studied journalism and public relations at the University of Texas at Austin, and that training shows in how he reads a Supreme Court ruling and translates it for the person sitting across the table. He does not hand you a press release. He hands you the actual holding, the actual scope, and the actual options that remain. Ralph leads our firm’s mass-tort and toxic-exposure work, and he has seen how a major appellate ruling reshapes a litigation docket — not in theory, but in the cases it strengthens, the cases it weakens, and the cases that survive because someone read the opinion carefully and pled the right theory.
Lupe Peña spent years inside a national insurance-defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue people exactly like the ones we now represent. He knows how Colossus values a claim, how IME doctors are selected, how surveillance works, and how a corporate defendant uses a favorable ruling to squeeze settlement values down. He brings that insider knowledge to our side of the table, and he conducts full consultations in Spanish without an interpreter. If your family processes this kind of news in Spanish — at the kitchen table, with your spouse, with your parents — Lupe can have that conversation in the language you actually think in.
We handle toxic tort claims and wrongful death cases for people who have been injured by products that were supposed to be safe. The Roundup ruling is a significant legal development, and it requires a response that is precise, honest, and grounded in the actual law — not in fear, not in false optimism, and not in a headline.
We offer a free consultation, twenty-four hours a day, seven days a week — and you will speak to a live person, not an answering service. We work on contingency: we do not get paid unless we win your case. If you call us and we are not the right fit for your situation, we will tell you. But if you have a Roundup claim and you want to know what actually survives this ruling, call us at 1-888-ATTY-911.
Frequently Asked Questions
Does the Supreme Court ruling mean Roundup is safe?
No. The Supreme Court ruled on a legal question about federal preemption — whether FIFRA, the federal pesticide law, prevents state courts from imposing labeling requirements different from what the EPA approved. The Court did not conduct a scientific review of glyphosate’s carcinogenicity. The IARC classification of glyphosate as “probably carcinogenic to humans” remains unchanged. The ruling is about who has authority to decide what goes on a pesticide label, not about whether the chemical causes cancer.
Can I still file a new Roundup lawsuit?
Potentially, yes — but the theory of your case matters more now than it ever did before. A pure failure-to-warn claim may be preempted by the ruling. However, claims based on design defect, fraudulent concealment, or negligent failure to test may survive because they challenge the product’s design or the company’s conduct rather than the label content. You should consult with an attorney who has read the ruling and can evaluate whether your specific facts support a surviving theory.
What happens to my existing Roundup claim?
Your existing claim is not automatically dismissed. The ruling affects the failure-to-warn theory, but your case may include other theories — design defect, fraudulent concealment, negligent testing — that are not necessarily preempted. Your attorney should be conducting a case-by-case review of your pleadings to identify which theories survive and whether amended pleadings are needed to assert those theories. If your attorney has not contacted you about the ruling’s impact on your specific case, you should call and ask directly.
Will the settlements already offered be affected?
Bayer and Monsanto may attempt to renegotiate or withdraw settlement offers that were based on failure-to-warn claims, arguing that the ruling reduces the value of those claims. If you have received a settlement offer, do not accept or reject it without consulting with an attorney who can evaluate whether the offer reflects the actual remaining value of your case. Some offers may still be fair; others may be artificially depressed by a defense reading of the ruling that overstates its scope.
What legal theories can still work after this ruling?
Three theories have the strongest argument for surviving FIFRA preemption: (1) design defect, which challenges the product’s formulation rather than its label; (2) fraudulent concealment, which targets Monsanto’s alleged suppression of scientific evidence about cancer risk; and (3) negligent failure to test, which challenges the company’s pre-market conduct rather than label content. Fraudulent concealment is the highest-value surviving theory because it supports punitive damages if the internal Monsanto documents demonstrate scienter — knowledge of the risk and intent to suppress it.
How long do I have to file a Roundup claim?
The statute of limitations varies by state — typically between two and six years for personal injury and one to three years for wrongful death. Many states apply a discovery rule for toxic exposure cases, meaning the clock may start when you discovered the connection between your cancer and your Roundup use, not when you were exposed. However, some states have statutes of repose that impose an outer deadline regardless of discovery. The Supreme Court ruling does not extend your deadline. You should confirm the specific deadline that applies to your state and situation with an attorney as soon as possible.
What evidence do I need for a Roundup case?
Four categories of evidence matter: (1) your individual exposure history — how long, how often, and how intensely you used Roundup; (2) your complete medical records — pathology report, treatment history, current prognosis; (3) Monsanto/Bayer internal corporate documents already in the MDL discovery record — emails, memos, and regulatory correspondence that show what the company knew and when; and (4) the IARC monograph and EPA registration file, which establish the scientific-regulatory disagreement at the heart of the case. Your exposure history is the most time-sensitive — memory fades and records are discarded, so documenting it in writing now is critical.
Should I accept a settlement offer right now?
Not without a case-by-case evaluation by an attorney who understands the ruling’s actual scope. A settlement offer made after this ruling may reflect a defense calculation that assumes all your claims are preempted — which may be true for failure-to-warn but may not be true for surviving theories. Accepting a settlement based on an overstated reading of the ruling could mean giving up a claim that has real value on a different theory. The decision to settle should be made after your attorney has reviewed your specific facts, identified your surviving claims, and assessed their value.
Does this ruling affect cases outside the Roundup MDL?
Yes — potentially in two ways. First, the ruling binds every federal court nationwide and will strongly shape state-court litigation strategy in every jurisdiction. Second, because FIFRA governs all pesticides and herbicides, not just glyphosate, the preemption logic may extend to failure-to-warn claims involving any EPA-registered pesticide product. If you have a claim involving a different pesticide or herbicide, this ruling may affect your case, and you should consult with an attorney who understands the FIFRA preemption analysis.
What if I used a generic glyphosate product instead of Roundup?
If you used a glyphosate product manufactured by a company other than Monsanto, your case may involve a different defendant and a different analysis. The FIFRA preemption ruling would still apply to the extent it addresses state failure-to-warn claims about EPA-approved labels, but the specific facts of your exposure, the defendant’s conduct, and the available evidence would differ. You should discuss your specific product history with an attorney.
Is it too late to file a Roundup claim?
That depends on your state’s statute of limitations and when you discovered the connection between your cancer and your Roundup use. In some states, the discovery rule means the clock may have started when you were diagnosed or when you first learned that Roundup could cause cancer. If you are within the applicable deadline — and many people who were recently diagnosed or who only recently learned of the connection still are — you may still be able to file. But you should confirm your deadline with an attorney immediately, because this ruling does not extend it.
Does this ruling affect my right to a jury trial?
The ruling narrows the scope of what a jury can decide in a Roundup case. Under the preemption ruling, a jury cannot hold Monsanto liable for failing to warn about cancer risk if the EPA’s label approval controls that question. However, a jury may still be able to decide whether Roundup was defectively designed, whether Monsanto fraudulently concealed evidence of cancer risk, and whether the company negligently failed to test the product adequately. Your right to a jury trial on those surviving theories is not eliminated — but the questions the jury is allowed to answer are narrower than they were before the ruling.
Your Next Step
If you or someone you love used Roundup and later developed non-Hodgkin lymphoma, the Supreme Court ruling is not the end of your story — but it is a moment that demands precise, honest legal guidance. The difference between a case that dies and a case that survives this ruling may come down to whether your attorney read the opinion, understood its limits, and pled the right theory. That work starts with a phone call.
Call us at 1-888-ATTY-911. The consultation is free. We do not get paid unless we win your case. And if we are not the right firm for your situation, we will tell you — because the one thing you deserve right now is the truth, delivered by people who know the law and respect you enough to speak it plainly.
Hablamos Español. Lupe Peña conducts full consultations in Spanish without an interpreter — because the hardest conversations about your health, your family, and your rights should happen in the language you actually think in.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Contacting our firm is free and confidential.